FDA Orders AbbVie to Stop Recruiting in Myeloma Trial After Deaths Spike

Drug Industry Daily
A A
The FDA has ordered AbbVie to stop recruiting multiple myeloma patients for a Phase III trial of its anti-cancer drug Venclexta/Venclyxto, the company announced Wednesday.

To View This Article:

Login

Subscribe To Drug Industry Daily